<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409808</url>
  </required_header>
  <id_info>
    <org_study_id>S62660</org_study_id>
    <nct_id>NCT04409808</nct_id>
  </id_info>
  <brief_title>IRIS Alfa Clinical Trial</brief_title>
  <acronym>IRIS</acronym>
  <official_title>IRIS Alfa Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To perform a safety study on the prototype IRIS vitrectomy device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of intra-operative adverse events that determine the safety of the surgery</measure>
    <time_frame>Intraoperative (surgery day)</time_frame>
    <description>complications VTX: iatrogenic tear, lens touch, choroidal/subretinal/vitreous hemorrhage, infusion suprachoroidal, iatrogenic retina trauma, posterior capsule tear, corneal eptihelial damage, hyphema, corneal edema, iris trauma, nucleus fragment in vitreous, posterior capsule tear, retinal incarceration, zonulae rupture with vitreous prolapse, subretinal PFCL, suprachoroidal silicone oil, zonulae dialysis, lens exchange required, other IOL problem</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Vitrectomy</condition>
  <arm_group>
    <arm_group_label>IRIS vitrectomy device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IRIS</intervention_name>
    <description>prototype IRIS vitrectomy device.</description>
    <arm_group_label>IRIS vitrectomy device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that are scheduled for vitrectomy surgery, regardless of the indication

          -  Both vitrectomy-only and combined phaco-vitrectomy surgeries

          -  Primary or repeat vitrectomy

          -  General or local anesthesia, or combination

          -  All ages

          -  Informed consent (from parents in patients &lt;18 years old)

        Exclusion Criteria:

          -  Unable to obtain informed consent from patient (or from parents in children)

          -  No post-operative 8 week visit is anticipated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Ingeborg Vriens, Mrs</last_name>
      <phone>00 32 16342229</phone>
      <email>ingeborg.vriens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Stalmans, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

